Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review
ObjectiveHealth Technology Assessment (HTA) is a comprehensive and important tool for assessment and decision-making in public health and healthcare practice. It is recommended by the WHO and has been applied in practice in many countries, mostly the developed ones. HTA might be an important tool to...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.898225/full |
| _version_ | 1818501548206981120 |
|---|---|
| author | Chiranjivi Adhikari Chiranjivi Adhikari Rojana Dhakal Rojana Dhakal Lal Mani Adhikari Bijaya Parajuli Khem Raj Subedi Yeshoda Aryal Arjun Kumar Thapa Komal Shah |
| author_facet | Chiranjivi Adhikari Chiranjivi Adhikari Rojana Dhakal Rojana Dhakal Lal Mani Adhikari Bijaya Parajuli Khem Raj Subedi Yeshoda Aryal Arjun Kumar Thapa Komal Shah |
| author_sort | Chiranjivi Adhikari |
| collection | DOAJ |
| description | ObjectiveHealth Technology Assessment (HTA) is a comprehensive and important tool for assessment and decision-making in public health and healthcare practice. It is recommended by the WHO and has been applied in practice in many countries, mostly the developed ones. HTA might be an important tool to achieve universal health coverage (UHC), especially beneficial to low-and-middle-income countries (LMIC). Even though the Package for Essential Non-communicable Diseases (PEN) has already been initiated, there is a clear policy gap in the HTA of any health device, service, or procedure, including the assessment of cardiovascular risk factors (CVRFs) in Nepal. Hence, we carried out the review to document the HTA supported evidence of hypertension and diabetes screening, as CVRFs in Nepal.Materials and methodsWe searched in PubMed, Cochrane, and Google Scholar, along with some gray literature published in the last 6 years (2016–2021) in a systematic way with a controlled vocabulary using a well-designed and pilot tested search strategy, screened them, and a total of 53 articles and reports that matched the screening criteria were included for the review. We then, extracted the data in a pre-designed MS-Excel format, first in one, and then, from it, in two, with more specific data.ResultsOf 53 included studies, we reported the prevalence and/or proportion of hypertension and diabetes with various denominators. Furthermore, HTA-related findings such as cost, validity, alternative tool or technology, awareness, and intervention effectiveness have been documented and discussed further, however, not summarized due to their sparingness.ConclusionOverall, the prevalence of DM (4.4–18.8%) and HTN (17.2–70.0%) was reported in most studies, with a few, covering other aspects of HTA of DM/HTN. A national policy for establishing an HTA agency and some immediately implementable actions are highly recommended. |
| first_indexed | 2024-12-10T20:57:43Z |
| format | Article |
| id | doaj.art-4b4cbcc282134a38bea8a5e9a9acc16c |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-10T20:57:43Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-4b4cbcc282134a38bea8a5e9a9acc16c2022-12-22T01:33:55ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-08-01910.3389/fcvm.2022.898225898225Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping reviewChiranjivi Adhikari0Chiranjivi Adhikari1Rojana Dhakal2Rojana Dhakal3Lal Mani Adhikari4Bijaya Parajuli5Khem Raj Subedi6Yeshoda Aryal7Arjun Kumar Thapa8Komal Shah9Department of Public Health, SHAS, Pokhara University, Pokhara, NepalIndian Institute of Public Health Gandhinagar, Gandhinagar, IndiaDepartment of Nursing, School of Health and Allied Sciences, Pokhara University, Pokhara, NepalDepartment of Life and Health Sciences, University of Nicosia, Nicosia, CyprusHealth Research and Social Development Forum International, Kathmandu, NepalMinistry of Health and Population, Gandaki Province, Myagdi Health Office, Myagdi, NepalDepartment of Economics, Far Western University, Tikapur Multiple Campus, Kailali, NepalMinistry of Health and Population, Kathmandu, NepalDepartment of Economics, School of Humanities and Social Sciences, Pokhara University, Pokhara, NepalIndian Institute of Public Health Gandhinagar, Gandhinagar, IndiaObjectiveHealth Technology Assessment (HTA) is a comprehensive and important tool for assessment and decision-making in public health and healthcare practice. It is recommended by the WHO and has been applied in practice in many countries, mostly the developed ones. HTA might be an important tool to achieve universal health coverage (UHC), especially beneficial to low-and-middle-income countries (LMIC). Even though the Package for Essential Non-communicable Diseases (PEN) has already been initiated, there is a clear policy gap in the HTA of any health device, service, or procedure, including the assessment of cardiovascular risk factors (CVRFs) in Nepal. Hence, we carried out the review to document the HTA supported evidence of hypertension and diabetes screening, as CVRFs in Nepal.Materials and methodsWe searched in PubMed, Cochrane, and Google Scholar, along with some gray literature published in the last 6 years (2016–2021) in a systematic way with a controlled vocabulary using a well-designed and pilot tested search strategy, screened them, and a total of 53 articles and reports that matched the screening criteria were included for the review. We then, extracted the data in a pre-designed MS-Excel format, first in one, and then, from it, in two, with more specific data.ResultsOf 53 included studies, we reported the prevalence and/or proportion of hypertension and diabetes with various denominators. Furthermore, HTA-related findings such as cost, validity, alternative tool or technology, awareness, and intervention effectiveness have been documented and discussed further, however, not summarized due to their sparingness.ConclusionOverall, the prevalence of DM (4.4–18.8%) and HTN (17.2–70.0%) was reported in most studies, with a few, covering other aspects of HTA of DM/HTN. A national policy for establishing an HTA agency and some immediately implementable actions are highly recommended.https://www.frontiersin.org/articles/10.3389/fcvm.2022.898225/fullhealth technology assessment (HTA)cardiovascularrisk factorhypertensiondiabetesscreening |
| spellingShingle | Chiranjivi Adhikari Chiranjivi Adhikari Rojana Dhakal Rojana Dhakal Lal Mani Adhikari Bijaya Parajuli Khem Raj Subedi Yeshoda Aryal Arjun Kumar Thapa Komal Shah Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review Frontiers in Cardiovascular Medicine health technology assessment (HTA) cardiovascular risk factor hypertension diabetes screening |
| title | Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review |
| title_full | Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review |
| title_fullStr | Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review |
| title_full_unstemmed | Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review |
| title_short | Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review |
| title_sort | need for hta supported risk factor screening for hypertension and diabetes in nepal a systematic scoping review |
| topic | health technology assessment (HTA) cardiovascular risk factor hypertension diabetes screening |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.898225/full |
| work_keys_str_mv | AT chiranjiviadhikari needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT chiranjiviadhikari needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT rojanadhakal needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT rojanadhakal needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT lalmaniadhikari needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT bijayaparajuli needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT khemrajsubedi needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT yeshodaaryal needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT arjunkumarthapa needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview AT komalshah needforhtasupportedriskfactorscreeningforhypertensionanddiabetesinnepalasystematicscopingreview |